DecImmune Therapeutics, a Cambridge, MA-based company that develops novel peptides and antibodies for acute, tissue damaging inflammation in myocardial infarction, burns, and other conditions involving vascular injury and reperfusion, completed a $2.25m equity financing.
Backers included new investor Broadview Ventures, and existing investors Astellas Venture Management and HealthCare Ventures.
The company intends to use the capital to develop its proprietary antibody therapeutic toward IND filing.
Founded by Michael Carroll PhD (Boston Childrens’ Hospital, Harvard Medical School), and Francis Moore Jr. MD (Brigham and Women’s Hospital, Harvard Medical School), DecImmune is advancing a therapeutic program targeting heart failure (by reducing tissue damage and improve ventricular function associated with myocardial infarction) as an adjunct to current standards of care
Led by Dr. Walter Newman, Chief Scientific Officer, the company is also investigating this approach to reduce tissue damage for a range of other acute and chronic post-injury settings.
FinSMEs
26/02/2013